NEW! CD19 expression cell line panels

Imanis Life Sciences

 Menu
0 items
Checkout

Nalm6 (Leukemia)

Description

Nalm6 is a B cell precursor leukemia cell line initiated from an adolescent male with acute lymphoblastic leukemia.1 The Nalm6 cell line is widely used for immune-oncology research, and the cells are part of the LL-100 blood cancer cell line panel, which consists of highly characterized leukemia and lymphoma cell lines for which whole-exosome and RNA sequencing is available.2,3

Nalm6 cells express relatively high levels of the tumor antigen CD194 and are frequently used a target cells in CD19-CAR-T cell killing and proliferation/activation assays.5,6 The cells are also frequently used as targets in the development of CD19 bi-specific antibodies and natural killer cell therapies.7,8 The cells express very low levels of the other tumor antigen targets CD204 and BCMA.9

Nalm6 cells exhibit tumorgenicity in immunocompromised (e.g., NSG, SCID-beige) mice and are frequently used for in vivo pre-clinical research. The cells form primary tumors when implanted subcutaneously,10 and experimental metastases to bone marrow, liver, spleen, lymph nodes, and the periodontal region are observed following intravenous implantation.11,12

The Imanis Nalm6 cell line originates from the ATCC Nalm6, clone G5 cell line (ATCC® CRL-3273TM)*, which was deposited at ATCC in 2010.

Stable reporter cell lines for immune-oncology research:

Our Nalm6 reporter cell lines can be used for in vitro or in vivo research. The luciferase (Fluc) and green fluorescence protein (GFP) reporters facilitate easy quantitation of cells for in vitro assays. Additionally, luciferase can be used for tracking tumor growth non-invasively in living animals through bioluminescence imaging.

Our Nalm6-Fluc-Puro CD19 panel includes cell lines that overexpress luciferase as well as various surface receptor densities (undetectable, low, mid, and endogenous levels) of oncology target CD19.
Our cells are generated by lentiviral vector transduction, ensuring high, constitutive expression of the transgenes. The lentiviral vectors used for these transductions are self-inactivating (SIN) vectors in which the viral enhancer and promoter has been deleted. This increases the biosafety of the lentiviral vectors by preventing mobilization of replication competent viruses.13

References:

  1. Minowada, J, et al. (1978). Human Leukemia Cell Lines: Evidence for Differentiation Toward T- and B-cell Axis within a Leukemia. Am. Assoc. Cancer Res. 19: 109.
  2. Quentmeier, H, et al. (2019). The LL-100 panel: 100 cell lines for blood cancer studies. Scientific Reports 9: 8218.
  3. Drexler, H.G. and Quentmeier, H. (2020) The LL-100 Cell Lines Panel: Tool for Molecular Leukemia-Lymphoma Research.  J. Mol. Sci. 21: 5800.
  4. Flavell, DJ, et al. (2006). The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma. Br J Haematol. 134: 157-170.
  5. Lintao, L, et al. (2020). Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9. Nat Communication 11: 5902.
  6. An, N, et al. (2016). Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells. Oncotarget 7: 10638-10649.
  7. Hill, TF, et al. (2023). Human plasma cells engineered to secrete bispecifics drive effective in vivoleukemia killing. bioRxiv doi: 1101/2023.08.24.554523.
  8. Lelaidier, M, et al. (2015). TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells. Oncotarget 6: 29440-29455.
  9. Bluhm, J, et al. (2018). CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin’s Lymphoma and Multiple Myeloma. Mol Ther 26:1906-1920.
  10. Sakemura, R, et al. (2021) Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-Cell Expansion, Trafficking, and Toxicity. Can Immunol Res 9: 1035-1046.
  11. Brentjens, RJ, et al. (2007) Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 13: 5426-5435.
  12. Barrett, DM, et al. (2011) Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood 118: e112-e117.
  13. Miyoshi, H, et al.(1998). Development of a self-inactivating lentivirus vector. Journal of Virology 72: 8150-8157.

*The ATCC trademark and trade name and any and all ATCC catalog numbers are trademarks of the American Type Culture Collection.

Learn More